Suven Life Sciences share news and announcements
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Last close ₹261.35down ₹6.85 (2.55%)BSE ₹261.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹268.20.
52-week range of traded prices to 23 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹7,385 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 10,72,06841.2% delivered
Suven Life Sciences orders, deals and press releases
305 filed, newest first. Page 5 of 7.
Aug 2013
Jul 2013
Jun 2013
May 2013
Apr 2013
Feb 2013
Jan 2013
Dec 2012
Nov 2012
Oct 2012
Aug 2012
Jul 2012
May 2012
Apr 2012
Feb 2012
Jan 2012
Dec 2011
Nov 2011
Oct 2011
Sep 2011
Aug 2011
Jul 2011
Jun 2011
May 2011
Apr 2011
Jan 2011
Dec 2010
Nov 2010
12 Nov · Business
Compensation Committee of Board of Directors of the Company allotted 1,95,740 equity shares through circular resolution on November 12, 2010 to the employees under stock option plans of the company. Further, consequent to the above allotment, the paid up share capital of the company has gone up from 116536248 equity shares of Re 1/- each aggregating to Rs. 11,65,36,248 to 116731988 equity shares of Re 1/- each aggregating to Rs 11,67,31,988.
Oct 2010
Sep 2010
Jul 2010